コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 io model of a homologous Leishmania donovani nucleoside transporter.
2 ucleoside kinase as well as an equilibrative nucleoside transporter.
3 database may function as a broadly selective nucleoside transporter.
4 d dipyridamole-sensitive human equilibrative nucleoside transporter.
5 boside (NBMPR), a potent inhibitor of the es nucleoside transporter.
6 was taken up inefficiently through a P1-type nucleoside transporter.
7 purines from their hosts via nucleobase and nucleoside transporters.
8 ther deoxynucleosides, through equilibrative nucleoside transporters.
9 ties from previously characterized mammalian nucleoside transporters.
10 emichannels, ABC protein family members, and nucleoside transporters.
11 nd formation over 3'-OH is essential for all nucleoside transporters.
12 lated in sequence to mammalian equilibrative nucleoside transporters.
13 genes encode functional adenosine/pyrimidine nucleoside transporters.
14 of a substrate-binding site in Na+-dependent nucleoside transporters.
15 diated by both facilitated and Na+-dependent nucleoside transporters.
16 (+)-driven, NBMPR-insensitive, concentrative nucleoside transporters.
17 transported across the cell membrane through nucleoside transporters.
18 ic distribution and cellular entry are human nucleoside transporters.
19 confirmed that AICAr enters cells via purine nucleoside transporters.
20 lyzed the expression and activity of various nucleoside transporters.
21 equilibrative (ENT) and concentrative (CNT) nucleoside transporters.
22 ansporter 1 (SGLT1) and of the concentrative nucleoside transporter 1 (CNT1) in the plasma membrane b
24 take into activated T cells by equilibrative nucleoside transporter 1 (ENT1) and inhibition of de nov
26 e of ticagrelor inhibiting the equilibrative nucleoside transporter 1 (ENT1) on platelets, leading to
28 iant of adenosine transporter, equilibrative nucleoside transporter 1 (ENT1), was associated with the
32 last extracellular loop of the equilibrative nucleoside transporter 1 (ENT1; also called SLC29a1) is
33 nd substrate interactions with equilibrative nucleoside transporter 1 (ENT1; SLC29A1) are known to be
34 transporter 1 (hENT1) or human concentrative nucleoside transporter 1 (hCNT1), when stably expressed
37 reviously shown that the human equilibrative nucleoside transporter 1 (hENT1) is expressed and functi
38 nucleoside transporters, human equilibrative nucleoside transporter 1 (hENT1) or human concentrative
39 trations specifically to human equilibrative nucleoside transporter 1 (hENT1) produced in recombinant
40 ansport was dominated by human equilibrative nucleoside transporter 1 (hENT1) under both growth condi
42 de the activities of the human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (
46 the most virulent species, the equilibrative nucleoside transporter 1 (PfENT1) represents the primary
47 thymidine kinase 1 (TK-1), and equilibrative nucleoside transporter 1 (SLC29A1) in HCC compared with
48 KBP-dependent inhibitor of the equilibrative nucleoside transporter 1 and is efficacious in an animal
49 inhibited adenosine uptake via equilibrative nucleoside transporter 1 and synergistically enhanced ad
51 ing the PPM transporter PfNT1 (P. falciparum nucleoside transporter 1) are auxotrophic for hypoxanthi
52 xogenous apical protein, CNT1 (concentrative nucleoside transporter 1), and found no increase in CNT1
53 xin43, connexin37, pannexin-1, equilibrative nucleoside transporter 1, CD39, CD73, ecto-nucleotide py
55 mputational model of the Leishmania donovani nucleoside transporter 1.1 (LdNT1.1) that captured this
56 smembrane domains of the Leishmania donovani nucleoside transporter 1.1, LdNT1.1, which transports ad
57 c adenosine transporter, ENT1 (equilibrative nucleoside transporter 1; Slc29a1), show no transition f
58 inically used vasodilator with equilibrative nucleoside transporters 1 and 2 (ENT1 and ENT2) inhibito
59 y transfected the cloned human equilibrative nucleoside transporters 1 and 2 (hENT1 and hENT2) into n
61 side transporter family member equilibrative nucleoside transporter-1 (ENT1) in the regulation of car
62 he effect on tumor immunity of equilibrative nucleoside transporter-1 (ENT1), the major regulator of
64 iscovered a role for the human concentrative nucleoside transporter-1 (hCNT1; SLC28A1), a high-affini
66 hat are deficient in the human equilibrative nucleoside transporter-1, the IC(50) of GemC18-NPs was o
67 ine-guanosine-specific Crithidia fasciculata nucleoside transporter 2 (CfNT2) that had gained the abi
68 rimental studies revealed that equilibrative nucleoside transporter 2 (ENT2), but not ENT1, is capabl
70 eoside transporter 1 (ENT1) or concentrative nucleoside transporter 3 (CNT3) increased RBV uptake in
71 e, we establish that the human concentrative nucleoside transporter 3 (CNT3) interacts with antiviral
72 we found that mice lacking the equilibrative nucleoside transporter 3 (ENT3) developed a spontaneous
76 lationship (QSAR) of the human concentrative nucleoside transporter 3 (hCNT3) expressed in Xenopus la
77 We tested the hypothesis that endothelial nucleoside transporter acts as a barrier impeding the de
78 ve epithelial differentiation, expression of nucleoside transporters affecting gemcitabine response,
79 ptake depends predominantly on equilibrative nucleoside transporters after conversion of AMP to adeno
80 Significantly, PfNT1, unlike the mammalian nucleoside transporters, also has the capacity to transp
81 tance is reduced uptake into tumor cells via nucleoside transporters, although precise mechanisms are
82 le-genome RNAi screening reveals that the P2 nucleoside transporter and adenosine kinase are involved
83 oped through reduced RBV uptake via the ENT1 nucleoside transporter and antiviral efficacy was reduce
85 distinct sets of >80 transporters including nucleoside transporters and nutrient transporters making
86 tion and isolation of DNAs encoding parasite nucleoside transporters and the functional characterizat
87 f inosine did not require cellular uptake by nucleoside transporters and was partially reversed by bl
88 omorphic consequences of dysfunction of this nucleoside transporter, and importantly suggests a new m
89 ess dependent on deoxycytidine kinase and on nucleoside transporters, and it was resistant to cytidin
91 data provide the first direct evidence that nucleoside transporters are able to critically modulate
93 trate that the NBMPR-sensitive equilibrative nucleoside transporters are novel and unexpected targets
96 nal fluid (CSF) containing inhibitors of the nucleoside transporter but not with this solution plus a
98 tor agonists and inhibition of equilibrative nucleoside transporters by dipyridamole may have therape
100 ndent and was inhibited by the concentrative nucleoside transporter (CNT) blocker phloridzin but not
103 The human SLC28 family of concentrative nucleoside transporter (CNT) proteins has three members:
104 ne transporter proteins, human concentrative nucleoside transporter (CNT)1, CNT2, and CNT3, all of wh
105 em L and system y+L amino acid carriers; the nucleoside transporters cNT1 and 2, eNT1 and 2, and the
106 how differential expression of concentrative nucleoside transporters (CNT1 and CNT2) prompted us to s
115 riboside (NBMPR)-insensitive, equilibrative nucleoside transporter ei by functional complementation
117 predict drug interactions with equilibrative nucleoside transporter (ENT) 1 and ENT2 using Bayesian m
119 g intracellular uptake via the equilibrative nucleoside transporter (ENT) ENT1 or the concentrative n
124 ury via adenosine receptors or equilibrative nucleoside transporter (ENT)-dependent intracellular ade
126 cloned human NBMPR-sensitive, equilibrative nucleoside transporter ENT1 and thus was designated ENT2
127 ed the positive correlation between SLC29A1 (nucleoside transporter ENT1) expression and potency of n
129 e show that the absence of the equilibrative nucleoside transporter (ENT1) in human red blood cells w
130 adenosine transporter, type 1 equilibrative nucleoside transporter (ENT1), drink more ethanol compar
131 lthioinosine (NBMPR)-sensitive equilibrative nucleoside transporter (ENT1), incubation with SB203580
132 aling by inhibiting the type 1 equilibrative nucleoside transporter (ENT1), whereas chronic ethanol e
134 o the function of 6BT as an inhibitor of the nucleoside transporter, ent1, which is thought to preven
135 te into cells deficient in the equilibrative nucleoside transporter ENT2, and reconstitution of ENT2
138 eoside transporters (CNTs) and equilibrative nucleoside transporters (ENTs) are important in physiolo
141 onsistent with the notion that equilibrative nucleoside transporters (ENTs) terminate adenosine signa
143 cellular compartment by way of equilibrative nucleoside transporters (ENTs), we hypothesized a functi
146 show that Slc29a1 (ENT-1) is the predominant nucleoside transporter expressed in the mouse testis.
148 ee transport mechanisms of the equilibrative nucleoside transporter family by which nucleosides and n
149 onstration that members of the equilibrative nucleoside transporter family can be electrogenic and es
151 us studies have implicated the equilibrative nucleoside transporter family member equilibrative nucle
152 Permeases belonging to the equilibrative nucleoside transporter family promote uptake of nucleosi
153 irst mammalian examples of the equilibrative nucleoside transporter family to be characterized, hENT1
154 d into cells by members of the equilibrative nucleoside transporter family, NR is predominantly metab
162 ani express two members of the equilibrative nucleoside transporter family; LdNT1 encoded by two clos
163 t required adenosine uptake by equilibrative nucleoside transporters followed by its (intracellular)
164 ion of a proton-dependent, broadly selective nucleoside transporter from Caenorhabditis elegans.
166 Asp389 and Arg393 residues within the LdNT2 nucleoside transporter from Leishmania donovani were mut
169 ent the crystal structure of a concentrative nucleoside transporter from Vibrio cholerae in complex w
170 rent M, 55,000 is immunologically related to nucleoside transporters from several other species and t
171 fui1Delta cells lacking the plasma membrane nucleoside transporter Fui1 confers sensitivity to the t
172 d residue of hENT1 that is important in both nucleoside transporter function and sensitivity to inhib
173 ase transporter gene or both NT3 and the NT2 nucleoside transporter gene resulted in pronounced upreg
177 s that human concentrative and equilibrative nucleoside transporters (hCNT1 and hENT1) are present on
179 relating its uptake with human equilibrative nucleoside transporter (hENT1) levels, stromal reaction,
182 A knockdown experiments demonstrate that the nucleoside transporter, hENT1, plays a key role in the c
185 sis, we have sought to determine whether the nucleoside transporters, human equilibrative nucleoside
186 e transporter 1 (hENT1) as the most abundant nucleoside transporter in leukemia cell lines and in AML
187 l inhibits uptake of adenosine by a specific nucleoside transporter in NG108-15 neuroblastoma x gliom
188 nscriptional riboswitch that downregulates a nucleoside transporter in response to binding guanine.
192 (hCNT1; SLC28A1), a high-affinity pyrimidine nucleoside transporter, in determining the chemosensitiv
193 ative 5-azacytidine-5'-elaidate (CP-4200), a nucleoside transporter-independent drug, persisted after
194 its uptake into cells through concentrative nucleoside transporters indicating a role for alternativ
195 treating CD56(bright)CD16(-) NK cells with a nucleoside transporter inhibitor, which increase extrace
196 OV-3 cells to dipyridamole, an equilibrative nucleoside transporter inhibitor; APCP, a CD73 (ecto-5'-
197 ls should assist the design of high-affinity nucleoside transporter inhibitors and substrates for bot
198 icantly enhanced in the presence of the ENT1 nucleoside transporter inhibitors dipyridamole and NBTI
199 ighly sensitive to inhibition by the classic nucleoside transporter inhibitors dipyridamole and nitro
202 cate that this phenomenon is mediated by the nucleoside transporters LdNT1 and LdNT2, as well as by t
203 at encode high affinity adenosine-pyrimidine nucleoside transporters LdNT1.1 and LdNT1.2 and that tra
204 nally constrained analogues of the potent es nucleoside transporter ligand, nitrobenzylmercaptopurine
205 Fun26, a homolog of human ENT (equilibrative nucleoside transporter), localizes to the vacuolar membr
206 , adenosine deaminase, and the equilibrative nucleoside transporter: mature receptors with complex gl
211 us uridine and the specific inhibitor of the nucleoside transporter, nitrobenzylthioinosine, did not
213 lass of integral membrane proteins, known as nucleoside transporters (NTs), for specific transport ac
215 lar cloning has isolated two subtypes of Na+-nucleoside transporters; one is pyrimidine-selective (N2
216 laevis oocytes expressing the P. falciparum nucleoside transporter PfNT1 established that this trans
218 transport of adenosine through equilibrative nucleoside transporter, raised the measured extracellula
219 entity to each other and to TbNT2, a P1 type nucleoside transporter recently identified in our labora
223 neurons, the expression profile of specific nucleoside transporter subtypes such as ENT1 is not esta
224 We have cloned the gene for a T. brucei nucleoside transporter, TbNT2, and shown that this perme
225 oved to be a broad selectivity, low affinity nucleoside transporter that could also transport adenine
227 nsported into hepatocytes by a Na+-dependent nucleoside transporter that is present in the canalicula
228 has the substrate specificity of the P1 type nucleoside transporters that have been previously charac
229 se models with dipyridamole, an inhibitor of nucleoside transporters that potentiates extracellular a
231 ify hENT3 as a mitochondrial and a lysosomal nucleoside transporter, the precise connections between
232 table to the direct release of adenosine via nucleoside transporters; the release of adenine nucleoti
234 scherichia coli mutant that lacked all known nucleoside transporters, whereas a phtD(+) allele did no
235 Recently, we constructed a broadly selective nucleoside transporter which accepts both purine and pyr
236 osine transporter ENT1 (type 1 equilibrative nucleoside transporter), which provides protection for a
237 for this selectivity was shown to be ENT1, a nucleoside transporter, which facilitates intracellular
238 PfNT1 encodes a functional purine/pyrimidine nucleoside transporter whose expression is strongly deve
239 selective, hENT2 is a generally low affinity nucleoside transporter with 2.6-, 2.8-, 7.7-, and 19.3-f
240 ally and biochemically that LdNT2 is a novel nucleoside transporter with an unusual and strict specif
242 transporter 3 (ENT3), the only intracellular nucleoside transporter within the solute carrier 29 (SLC